<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371889</url>
  </required_header>
  <id_info>
    <org_study_id>821035</org_study_id>
    <secondary_id>821035</secondary_id>
    <secondary_id>R01AA023192</secondary_id>
    <nct_id>NCT02371889</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers</brief_title>
  <acronym>TOPG</acronym>
  <official_title>A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Corporal Michael J. Crescenz VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to advance the effort to develop personalized pharmacotherapy&#xD;
      for alcohol use disorders (AUDs). The investigators propose to conduct a 12-week,&#xD;
      prospective, randomized clinical trial of the moderating effect of rs2832407 on the efficacy&#xD;
      of TOP in reducing heavy drinking (HD) in 200 individuals of European descent with DSM-5 AUD.&#xD;
      The investigators will stratify the randomization on genotype and oversample rs2832407*C&#xD;
      homozygotes, the most TOP-responsive genotype, to ensure comparable numbers of patients in&#xD;
      the four medication x genotype groups. The investigators will use daily data collection to&#xD;
      examine changes in relevant process variables (e.g., alcohol expectancies) and their&#xD;
      interaction with genotype and medication group as predictors of HD. The proposed study is&#xD;
      innovative in that it will be the first prospective test of a pharmacogenetic hypothesis&#xD;
      involving TOP; it will use daily reports to examine expectancies and how they interact with&#xD;
      medication and genotype to predict HD; and it will enroll DSM-5 AUD patients whose goal is&#xD;
      either to reduce or stop drinking, which will increase the study's external validity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-week, prospective, randomized clinical trial of the moderating effect of&#xD;
      rs2832407 on the efficacy of topiramate in reducing HD in 200 individuals of European descent&#xD;
      with DSM-5 AUD. The investigators will stratify the randomization on genotype and oversample&#xD;
      rs2832407*C homozygotes, the most topiramate-responsive genotype, to ensure comparable&#xD;
      numbers of subjects in the four medication x genotype groups. The investigators will compare&#xD;
      the efficacy of topiramate to placebo in reducing the frequency of HDDs in subjects with AUD&#xD;
      using a two-arm, parallel-groups design. Subjects will either have a goal of reducing their&#xD;
      drinking to safe levels or abstinence.&#xD;
&#xD;
      The investigators will use daily data collection to examine changes in relevant process&#xD;
      variables and their interaction with genotype and medication group as predictors of HD. At&#xD;
      each visit, all subjects will receive Medication Management (Pettinati, Weiss et al. 2004),&#xD;
      which was developed for the COMBINE Trial and which the investigators modified to be relevant&#xD;
      for both reducing heavy drinking and promoting abstinence. Random assignment to treatment&#xD;
      group and double-blind conditions will be maintained throughout the study. Raters will be&#xD;
      trained in the reliable use of all assessments. The investigators will use serum GGTP and&#xD;
      percent disialotransferrin (%dCDT), an improved assay for carbohydrate deficient transferrin,&#xD;
      to validate subject reports. Following a one-week pre-treatment assessment period, subjects&#xD;
      will receive 12 weeks of treatment, after which there will be a 6-day taper period, during&#xD;
      which subjects will reduce their dosage of topiramate gradually and then discontinue it&#xD;
      completely. Daily reports during the treatment period will be obtained using interactive&#xD;
      voice response (IVR) to identify subjective correlates of medication effects and to monitor&#xD;
      medication use. Following the 12-week treatment period, subjects will be asked to return to&#xD;
      the clinic for 3-month and 6-month post-treatment follow-up visits to evaluate the durability&#xD;
      of treatment effects.&#xD;
&#xD;
      Two hundred men and women of European descent will be randomized to study medication.&#xD;
      Subjects will be recruited using referrals from treatment programs throughout Philadelphia;&#xD;
      IRB-approved advertisements on mass transit, on local radio and television stations and in&#xD;
      newspapers, social media, and broadcast email messages at institutions that offer such a&#xD;
      service and by posting/distributing recruitment materials in community and college settings.&#xD;
      Respondents will initially be evaluated by telephone prior to an in-person visit to the&#xD;
      Treatment Research Center of the University of Pennsylvania Perelman School of Medicine. The&#xD;
      investigators will select subjects based on their genotype to ensure comparable numbers of&#xD;
      individuals who are rs2832407*C-allele homozygotes and A-allele carriers. The investigators&#xD;
      will block randomize subjects to balance the groups on treatment goal (i.e., reduced drinking&#xD;
      or abstinence).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Heavy Drinking Days by Medication Group (Timeline Follow Back Calendar).</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of Heavy Drinking Days during 12 weeks of treatment in the topiramate and placebo groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Heavy Drinking Days Per Day by Medication and Genotype Group (Timeline Follow Back Calendar).</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of Heavy Drinking Days in the last week of the 12 week treatment phase by medication group and rs2832407 genotype group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numbers of Drinking Days Over 12 Weeks Treatment by Medication Group.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Numbers of drinking days over 12 week treatment phase by medication group. Data was collected using timeline follow back calendar.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse Effects in Study Participants (Questionnaire)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cumulative number of adverse events as assessed at each study visit to determine the safety of topiramate.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Use Disorder (AUD)</condition>
  <arm_group>
    <arm_group_label>Topiramate + Medical Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pill + Medical Management</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Max therapeutic dose of 200mg/day</description>
    <arm_group_label>Topiramate + Medical Management</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medical Management</intervention_name>
    <description>Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.</description>
    <arm_group_label>Placebo Pill + Medical Management</arm_group_label>
    <arm_group_label>Topiramate + Medical Management</arm_group_label>
    <other_name>MM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inactive Placebo</intervention_name>
    <description>In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day</description>
    <arm_group_label>Placebo Pill + Medical Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Determined to be physically healthy, based on medical history and physical examination&#xD;
             and approval of the study physician&#xD;
&#xD;
          2. Age 18 to 70 years, inclusive&#xD;
&#xD;
          3. Self-identified European ancestry&#xD;
&#xD;
          4. Meets DSM-5 criteria for AUD&#xD;
&#xD;
          5. Average weekly ethanol consumption of &gt;24 standard drinks for men and &gt;18 standard&#xD;
             drinks for women, with a weekly average of &gt; 2 HDDs during the month before screening&#xD;
&#xD;
          6. Stated goal to reduce drinking to safe levels or to stop drinking&#xD;
&#xD;
          7. Able to read English at an 8th grade or higher level and no gross cognitive impairment&#xD;
&#xD;
          8. Willingness to nominate an individual who will know the subject's whereabouts to&#xD;
             facilitate follow up during the study&#xD;
&#xD;
          9. Women of child-bearing potential (i.e., who have not had a hysterectomy, bilateral&#xD;
             oophorectomy, tubal ligation or is less than two years postmenopausal): must be&#xD;
             non-lactating and practicing a reliable method of birth control, and have a negative&#xD;
             urine pregnancy test prior to the initiation of treatment. Examples of medically&#xD;
             acceptable methods for this protocol include: the birth control pill, intrauterine&#xD;
             device, injection of Depo-Provera, Norplant, contraceptive patch, contraceptive ring,&#xD;
             double-barrier methods (such as condoms and diaphragm/spermicide), male partner&#xD;
             sterilization, abstinence (and agreement to continue abstinence or to use an&#xD;
             acceptable method of contraception, as listed above, should sexual activity commence),&#xD;
             and tubal ligation.&#xD;
&#xD;
         10. Willingness to provide signed, informed consent and commit to completing the&#xD;
             procedures in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A current, clinically significant physical disease or abnormality on the basis of&#xD;
             medical history, physical examination, or routine laboratory evaluation, including&#xD;
             direct bilirubin elevations of &gt;110% or a transaminase elevation &gt;300% of normal&#xD;
&#xD;
          2. A history of nephrolithiasis&#xD;
&#xD;
          3. A history of glaucoma&#xD;
&#xD;
          4. Current treatment with carbonic anhydrase inhibitors, due to the added risk of&#xD;
             metabolic acidosis.&#xD;
&#xD;
          5. Current, serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe or&#xD;
             psychotic major depression, panic disorder, borderline or antisocial personality&#xD;
             disorder, organic mood or mental disorders, eating disorder, or imminent suicide or&#xD;
             violence risk)&#xD;
&#xD;
          6. Current DSM-IV diagnosis of dependence on a drug other than alcohol or nicotine&#xD;
&#xD;
          7. A history of hypersensitivity to topiramate&#xD;
&#xD;
          8. Current regular treatment with a psychotropic medication (e.g., benzodiazepines,&#xD;
             antidepressants), which affect neurotransmitter systems, or a medication to treat&#xD;
             alcohol dependence&#xD;
&#xD;
          9. Currently taking any tricyclic antidepressant (e.g., Adapin (doxepin), Anafranil&#xD;
             (clomipramine), Elavil (amitryptyline), Pamelor (nortryptyline), Tofranil&#xD;
             (imipramine), Sinequan (doxepin)&#xD;
&#xD;
         10. Urine drug screen positive for recent use of opioids, cocaine, or amphetamines (may be&#xD;
             repeated once and if the result is negative on repeat it is not exclusionary)&#xD;
&#xD;
         11. Because co-administration of topiramate with dolutegravir reduced plasma&#xD;
             concentrations of the antiretroviral through induction of CYP3A, the use of&#xD;
             dolutegravir is exclusionary.&#xD;
&#xD;
         12. Judged by the principal investigator or his designee to be an unsuitable candidate for&#xD;
             receipt of an investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry R Kranzler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Corporal Michael J. Crescenz VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <results_first_submitted>February 1, 2021</results_first_submitted>
  <results_first_submitted_qc>February 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2021</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topiramate</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Personalized Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcoholic Intoxication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02371889/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02371889/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted from December 29, 2014 through August 1, 2019 at the University of Pennsylvania Treatment Research Center (Penn; n=164) and the Corporal Michael J. Crescenz Veterans Affairs Medical Center (CMCVAMC; n=6).</recruitment_details>
      <pre_assignment_details>Participants completed an in-person visit, where they gave informed consent, underwent a medical history, physical examination, routine clinical laboratory testing, a urine drug screen, and, if appropriate, pregnancy testing. We excluded 150 participants based on the first in-person visit based on the inclusion/exclusion criteria from the protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Topiramate + Medical Management</title>
          <description>Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Pill + Medical Management</title>
          <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse medication effect</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal time constraints</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topiramate + Medical Management</title>
          <description>Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Pill + Medical Management</title>
          <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="10.5"/>
                    <measurement group_id="B2" value="50" spread="12.8"/>
                    <measurement group_id="B3" value="51.2" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Married or cohabiting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CC genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AC/AA genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime Major Depression</title>
          <description>Lifetime episode of Major depression based on DSM-IV (SCID-I/P)(First et al. 2001).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CC genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AC/AA genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime Anxiety Disorder</title>
          <description>Lifetime episode of Anxiety based on DSM-IV (SCID-I/P)(First et al. 2001).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CC genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AC/AA genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinking Days 90days prior to screening</title>
          <description>Drinking day measured in standard drinks.</description>
          <units>Drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.2" spread="16.5"/>
                    <measurement group_id="B2" value="86.3" spread="16.8"/>
                    <measurement group_id="B3" value="86.5" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heavy drink days 90 days prior to screening</title>
          <description>Heavy drinking day measured as 5 or greater standard drinks for men and 4 or greater standard drinks for women in a day.</description>
          <units>Heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.8" spread="23.5"/>
                    <measurement group_id="B2" value="68.7" spread="25.6"/>
                    <measurement group_id="B3" value="68.9" spread="26.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Heavy Drinking Days by Medication Group (Timeline Follow Back Calendar).</title>
        <description>The number of Heavy Drinking Days during 12 weeks of treatment in the topiramate and placebo groups.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate + Medical Management</title>
            <description>Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill + Medical Management</title>
            <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Heavy Drinking Days by Medication Group (Timeline Follow Back Calendar).</title>
          <description>The number of Heavy Drinking Days during 12 weeks of treatment in the topiramate and placebo groups.</description>
          <units>Heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.00" spread="23.82"/>
                    <measurement group_id="O2" value="41.25" spread="26.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Heavy Drinking Days Per Day by Medication and Genotype Group (Timeline Follow Back Calendar).</title>
        <description>Number of Heavy Drinking Days in the last week of the 12 week treatment phase by medication group and rs2832407 genotype group.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype CC Topiramate + Medical Management</title>
            <description>Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
          <group group_id="O2">
            <title>Genotype CC Placebo Pill + Medical Management</title>
            <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
          <group group_id="O3">
            <title>Genotype AA/AC Topiramate + Medical Management</title>
            <description>opiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
          <group group_id="O4">
            <title>Genotype AA/AC Placebo Pill + Medical Management</title>
            <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Heavy Drinking Days Per Day by Medication and Genotype Group (Timeline Follow Back Calendar).</title>
          <description>Number of Heavy Drinking Days in the last week of the 12 week treatment phase by medication group and rs2832407 genotype group.</description>
          <units>Heavy drinking days during week 12</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="2.27"/>
                    <measurement group_id="O2" value="3.17" spread="2.69"/>
                    <measurement group_id="O3" value="2.24" spread="2.46"/>
                    <measurement group_id="O4" value="3.14" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Drinking Days Over 12 Weeks Treatment by Medication Group.</title>
        <description>Numbers of drinking days over 12 week treatment phase by medication group. Data was collected using timeline follow back calendar.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate + Medical Management</title>
            <description>Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill + Medical Management</title>
            <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Drinking Days Over 12 Weeks Treatment by Medication Group.</title>
          <description>Numbers of drinking days over 12 week treatment phase by medication group. Data was collected using timeline follow back calendar.</description>
          <units>Drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.58" spread="25.35"/>
                    <measurement group_id="O2" value="65.14" spread="22.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Effects in Study Participants (Questionnaire)</title>
        <description>Cumulative number of adverse events as assessed at each study visit to determine the safety of topiramate.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate + Medical Management</title>
            <description>Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill + Medical Management</title>
            <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects in Study Participants (Questionnaire)</title>
          <description>Cumulative number of adverse events as assessed at each study visit to determine the safety of topiramate.</description>
          <units>Number of adverse events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.7"/>
                    <measurement group_id="O2" value="2.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Frequency, type, and severity of adverse effects will be assessed at each study visit to determine the safety of topiramate.</desc>
      <group_list>
        <group group_id="E1">
          <title>Topiramate + Medical Management</title>
          <description>Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Pill + Medical Management</title>
          <description>Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit&#xD;
Medical Management: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>alcohol-related relapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>exacerbation of asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pain and discomfort</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Upper respiratory infections</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Speech/Language abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Henry R. Kranzler, M.D.</name_or_title>
      <organization>University of Pennsylvania Perelman School of Medicine</organization>
      <phone>215-746-1943</phone>
      <email>kranzler@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

